Krill Oil vs. Fish Oil on the Label: The EPA + DHA per Gram Math That Reverses the Price Story, the Phospholipid-vs-Triglyceride Bioavailability Question That Marketing Overstates, and the Serving-Size Trick That Hides How Many Softgels a 2 g/Day Dose Actually Costs

Walk into any supplement retailer and look at the omega-3 shelf. Two rows are almost always adjacent. On one row: bottles of fish oil at $10 to $35 for a 100-to-200-softgel supply. On the other row, frequently at the same eye level and often with more prominent shelf placement: bottles of krill oil at $30 to $80 for a 60-to-120-softgel supply, sometimes for as few as 30 softgels at that price. The pricing signal is the standard consumer-product cue for "premium" — krill oil costs more, so it must do more. The front-of-label marketing reinforces the framing: phospholipid-bound omega-3s for superior absorption, a natural astaxanthin content, marine-sustainability certifications, a cleaner aftertaste profile, sometimes a "clinically studied dose" claim.

The per-gram-of-active-omega-3 math on the Supplement Facts panel reverses the framing cleanly. A typical retail krill-oil softgel delivers 60 to 100 mg of combined EPA + DHA. A typical retail fish-oil softgel delivers 300 to 1000 mg of combined EPA + DHA, with pharmaceutical-grade concentrates delivering up to 850 mg from a 1 g softgel. The 2 g/day EPA + DHA dose that most of the cardiovascular, triglyceride-lowering, and anti-inflammatory literature is anchored to requires roughly 4 to 6 large krill-oil softgels per day (or 20 to 30 small ones at the low end of the krill-oil dose range) against 2 to 3 concentrated fish-oil softgels. Priced out at typical retail, the monthly cost of hitting 2 g EPA + DHA from krill oil frequently runs 5 to 15 times the fish-oil cost for the same milligrams of the active molecule.

There is a real bioavailability advantage on the krill side — phospholipid-bound omega-3s do incorporate into plasma phospholipids and red-cell membranes somewhat more efficiently than triglyceride or ethyl-ester fish-oil forms at matched dose. The peer-reviewed plasma-incorporation studies land the advantage in the 10 to 30 percent range depending on the endpoint. That is not zero. It is also not the story the retail price implies. A 10 to 30 percent efficiency advantage on an ingredient that costs 500 to 1500 percent more per gram of active is not a premium product on the value math — it is a marketing product with a real but overstated efficacy edge.

This post is the krill-vs-fish-oil label-literacy read. What each product actually delivers on the Supplement Facts panel. The serving-size trick that hides how many softgels the studied dose actually requires. The phospholipid-bioavailability question the marketing overstates. The astaxanthin-and-sustainability claims worth taking seriously and the ones worth taking with skepticism. The four label patterns that separate a transparent product from a marketing product. And the 20-second Supplement Facts read that shows which product is priced honestly against its active ingredient.

What Each Product Actually Delivers per Softgel

The critical thing to understand about any omega-3 supplement is that "fish oil" or "krill oil" is not the active ingredient. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the active ingredients. The oil is the delivery vehicle. What the buyer is paying for — or should be paying for — is milligrams of EPA + DHA delivered to the body. Every other number on the front of the label is marketing.

Standard fish oil (triglyceride form, uncrafted from the raw material) delivers 300 mg EPA + DHA per 1000 mg softgel. This is the 30 percent omega-3 concentration of raw fish oil from most oily-fish species (anchovy, sardine, mackerel). A 1000-mg softgel at 30 percent concentration delivers 180 mg EPA and 120 mg DHA, or 300 mg total. Two of these softgels per day deliver 600 mg EPA + DHA — a supplemental dose closer to the general-wellness intake floor than to any studied cardiovascular or anti-inflammatory endpoint.

Concentrated fish oil (triglyceride or re-esterified triglyceride form, molecularly distilled) delivers 500 to 800 mg EPA + DHA per 1000 mg softgel. This is the standard mid-range concentration on most reputable brands today. A 1000-mg softgel at 60 percent omega-3 concentration delivers 400 mg EPA and 200 mg DHA, or 600 mg total. Two softgels per day deliver 1.2 g EPA + DHA — closer to the studied range but still below the 2 to 4 g/day the cardiovascular literature is anchored on.

Pharmaceutical-grade or high-concentrate fish oil (rTG or ethyl-ester form) delivers 800 to 900 mg EPA + DHA per 1000 mg softgel. This is the concentration level of products like the Nordic Naturals ProOmega line, most Carlson concentrates, and the prescription products (Lovaza, Vascepa) at higher concentrations still. Two softgels per day deliver 1.6 to 1.8 g EPA + DHA. Two to three softgels per day comfortably hit the 2 to 4 g/day studied dose.

Krill oil delivers 60 to 100 mg EPA + DHA per 500 mg softgel, or 120 to 200 mg per 1000 mg softgel. This is the 12 to 20 percent omega-3 concentration of typical retail krill oil. Krill's natural composition is roughly 40 percent phospholipids, 30 percent triglycerides, 12 to 20 percent omega-3 fatty acids (EPA and DHA together), and the balance is other neutral lipids, water, and minor components including a small amount of astaxanthin. The 500 mg softgel size is common because larger krill-oil softgels become impractical (krill oil is denser than fish oil and the softgels are heavier).

Higher-concentration krill oil (superba-2, K-Real, and other trademarked concentrates) delivers 150 to 300 mg EPA + DHA per 1000 mg softgel. This is the upper end of what phospholipid-bound krill oil currently reaches without a re-esterification step that would defeat the phospholipid-form marketing claim. Two softgels per day at the high end deliver 600 mg EPA + DHA — the same as two 1000-mg standard fish-oil softgels at 30 percent concentration.

The gap is not subtle. A 1000 mg softgel of concentrated fish oil delivers roughly 4 to 8 times more EPA + DHA than a 1000 mg softgel of typical krill oil.

The Serving-Size Trick That Hides the Softgel Count

The most common label pattern that obscures the per-day EPA + DHA delivery is the serving-size definition. A krill-oil label frequently defines a "serving" as one softgel and reports EPA + DHA per serving at 60 to 100 mg, with the recommended use reading "one softgel daily with a meal." The buyer reads the label as one-a-day and one-serving-per-day and does the math against the number of softgels in the bottle (frequently 60 softgels for a 60-day supply at $40 to $60, computing to roughly $0.70 to $1.00 per serving).

Nothing on the front label tells the buyer that the studied cardiovascular and triglyceride-lowering dose is 2 g EPA + DHA per day. Nothing tells the buyer that one 60-mg softgel per day delivers 3 percent of that studied dose. To hit 2 g/day from that product, the buyer needs to take 20 to 30 softgels per day — burning through a 60-softgel bottle in two to three days at a cost of $400 to $900 per month for the studied dose.

The same trick appears in the reverse direction on fish-oil labels. A "standard fish oil" bottle at 1000 mg per softgel and 30 percent concentration delivers 300 mg EPA + DHA per softgel. The label reads "1000 mg fish oil per softgel" and the buyer reads that as their omega-3 dose. To hit 2 g EPA + DHA/day from that product requires 6 to 7 softgels per day. If the buyer takes the one-a-day dose implied by the container size, they are getting 15 percent of the studied dose.

The single most useful label read for any omega-3 product is the same across both categories: divide the studied dose (2 g EPA + DHA/day for cardiovascular and triglyceride endpoints, 3 to 4 g/day for inflammatory or joint endpoints, 1 g/day for the general-wellness intake floor) by the milligrams of EPA + DHA per softgel. That is the softgels-per-day count. Then multiply that count by the per-softgel cost from the bottle price divided by the serving count. That is the true daily cost of the dose the buyer is actually trying to reach.

The Bioavailability Question

The phospholipid-vs-triglyceride bioavailability comparison is where the krill-oil marketing story has some legitimate footing. The peer-reviewed literature on plasma phospholipid EPA + DHA incorporation, red-cell membrane omega-3 index, and cellular uptake of long-chain omega-3 fatty acids does support a modest efficiency advantage for the phospholipid-bound form at matched dose. The mechanism is anatomically reasonable — phospholipid-bound fatty acids arrive at the intestinal enterocyte in a form more directly usable for re-esterification into cellular phospholipids than triglyceride-bound fatty acids that require a lipolysis-then-reassembly step.

The magnitude of the advantage across the published literature lands in the 10 to 30 percent range for most endpoints at matched EPA + DHA dose over 4-to-12-week supplementation windows. Ramprasath 2013, Ulven 2011, Schuchardt 2011, and Kohler 2015 are the commonly cited studies showing the incorporation advantage. Some studies show the advantage collapsing to statistical non-significance when the fish-oil comparator is in the re-esterified triglyceride (rTG) form rather than the ethyl-ester (EE) form, which is the closest fair comparison because rTG is the form used in most reputable current retail fish-oil products.

The critical framing for the buyer: the bioavailability advantage does not compensate for the concentration gap. If krill oil at 60 mg EPA + DHA per softgel gives the body 30 percent more usable omega-3 per milligram delivered than fish oil at 500 mg EPA + DHA per softgel, the buyer is still getting 78 mg equivalent from the krill softgel against 500 mg from the fish-oil softgel. The bioavailability advantage narrows the gap; it does not close it. At retail price, one concentrated fish-oil softgel still delivers 6 to 8 times more effective EPA + DHA than one krill-oil softgel at roughly one-tenth the per-softgel cost.

Where the bioavailability advantage plausibly matters more: patients on very high fish-oil doses experiencing GI intolerance, patients who have failed to raise omega-3 index on fish oil at matched dose, patients whose lipase or bile-acid biology suggests reduced triglyceride hydrolysis efficiency. These are physician-guided edge cases, not the general population the retail marketing addresses.

The Astaxanthin Question

Krill oil contains naturally occurring astaxanthin, the carotenoid pigment that makes krill (and salmon that eat krill) pink. Astaxanthin is a legitimately interesting molecule with its own body of evidence for skin photoprotection, eye fatigue, and lipid-oxidation endpoints at studied doses of 6 to 12 mg per day. See our separate post on the astaxanthin 12 mg vs 4 mg dose gap for the full read.

The astaxanthin content in typical retail krill oil is 100 to 500 micrograms per gram of oil. A 500 mg softgel of krill oil delivers 50 to 250 micrograms of astaxanthin, or 0.05 to 0.25 mg. The studied astaxanthin dose is 12 mg. The delivered dose from a typical krill softgel is 0.4 to 2 percent of the studied dose.

Astaxanthin as a marketing bullet on a krill-oil label is a legitimate ingredient callout — the molecule is there. Astaxanthin as a functional dose from that same softgel is not what the label implies. To hit the studied astaxanthin dose from a krill softgel with 250 mcg would require 48 softgels per day. Buyers who want a functional astaxanthin dose should buy an astaxanthin supplement at the studied 12 mg dose directly; buyers who buy krill oil expecting the astaxanthin content to matter functionally are paying premium for a pixie-dusted co-ingredient.

The Sustainability Question

Krill-oil marketing frequently leads with sustainability certifications — Marine Stewardship Council (MSC), Antarctic and Southern Ocean Coalition (ASOC) references, "wild-caught in pristine Antarctic waters" language. The environmental science on krill fishing in the Southern Ocean is genuinely contested. Krill are the base of the Antarctic food web supporting whales, seals, penguins, and fish. The Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR) sets catch quotas that are currently well below theoretical maximum sustainable yield, but the concentration of fishing pressure in specific feeding grounds has been the subject of ongoing scientific concern. MSC certification of specific krill fisheries has been controversial in the marine-biology community.

Fish-oil sustainability tracks with the source fishery. Anchovy-based fish oils sourced from the Peruvian anchoveta fishery under IFFO-RS certification have generally sound sustainability profiles. Sardine and menhaden fisheries vary. The buyer who cares about sustainability should read the specific source fishery certification on the label rather than defaulting to the assumption that either "krill oil" or "fish oil" as a category is sustainable or unsustainable.

The consumer-facing takeaway: the sustainability marketing on krill oil is a real question the buyer can weigh alongside the cost-per-gram math, but the sustainability claim does not, by itself, justify a 5-to-15x price premium on the active ingredient. Sustainability is a values question. Cost-per-gram is a math question. Both should factor in independently.

The Four Label Patterns That Separate a Transparent Product From a Marketing Product

Front-label callout of EPA + DHA milligrams per softgel. A product that leads with "600 mg EPA + DHA per softgel" is telling the buyer what matters. A product that leads with "1200 mg krill oil per serving" or "1000 mg fish oil per softgel" is leading with the delivery vehicle and forcing the buyer to compute the active dose from the Supplement Facts panel.

Serving size defined as more than one softgel when the studied dose requires more than one softgel. A concentrated fish-oil product where the studied 2 g EPA + DHA dose requires 2 to 3 softgels per day and the serving size is defined as 2 softgels is transparent. A krill-oil product where the studied dose requires 20+ softgels per day and the serving size is defined as 1 softgel is obscuring.

Absolute EPA and DHA disclosure separately, not just combined. The two fatty acids have different physiologic roles — EPA anchors most of the anti-inflammatory and triglyceride-lowering literature, DHA anchors most of the neurologic and structural-membrane literature. A label that discloses "300 mg EPA, 200 mg DHA" per softgel is transparent. A label that discloses "500 mg omega-3" without breaking out EPA and DHA is opaque about which physiologic endpoint the buyer should expect.

Third-party purity and oxidation testing. Oxidized fish oil (measured by peroxide value, anisidine value, and TOTOX total oxidation) is nutritionally and possibly harmfully different from fresh fish oil. IFOS (International Fish Oil Standards) certification, USP verification, or NSF certification all include oxidation testing and third-party assay against label claim. Krill oil is less oxidation-vulnerable than fish oil because the phospholipid packaging and the natural astaxanthin function as antioxidants; certification still matters for label-claim accuracy.

The 20-Second Supplement Facts Read

Four questions to answer at the shelf before buying any omega-3 product:

1. What is the EPA + DHA milligram content per softgel? Divide the studied dose you are targeting (1 g/day general wellness, 2 g/day cardiovascular and triglyceride, 3 to 4 g/day inflammatory or joint) by that number. That is the softgels-per-day count for your dose. If the count is above 6 softgels per day, either the concentration is too low for your target dose or the product is designed for a general-wellness dose that does not match your goal.

2. What is the cost per gram of actual EPA + DHA? Multiply the softgels-per-day count by the per-softgel cost (bottle price divided by softgel count divided by servings per softgel). That is the daily cost of your dose. Multiply by 30 for the monthly cost. Compare across products at the same target dose — this is where the krill-vs-fish-oil comparison reverses cleanly against the retail-shelf price signal.

3. What is the form? Triglyceride, re-esterified triglyceride (rTG), ethyl ester (EE), or phospholipid (krill). Triglyceride and rTG have the strongest bioavailability profile in the triglyceride category and are what most reputable current fish-oil brands use. Ethyl ester is the older concentration technology and has slightly reduced bioavailability against triglyceride at matched dose. Phospholipid-form (krill) has the modest bioavailability advantage discussed above.

4. What is the third-party certification? IFOS, USP, NSF, or MSC-plus-oxidation-panel disclosure on the manufacturer website. Any product without third-party purity and oxidation testing is asking the buyer to trust the manufacturer's own assay, and the omega-3 market has enough label-claim variability in the third-party audit literature to make that trust unearned.

The retail-shelf price signal on the omega-3 category — krill oil visually premium, fish oil visually value — is one of the clearest cases in the supplement market where the front-of-label story and the per-gram-of-active math point in opposite directions. The bioavailability advantage of the phospholipid form is real. It is not 5-to-15x-price-premium real. Read the label, do the milligrams-per-softgel math, run the softgels-per-day count against your target dose, and let the number decide.